23 studies found for:    Pharmacyclics | Open Studies
Show Display Options
Rank Status Study
1 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors
Conditions: Breast Cancer;   Non-Small Cell Lung Cancer;   Pancreatic Cancer
Interventions: Drug: Ibrutinib;   Drug: MEDI4736
2 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Condition: Graft Versus Host Disease
Intervention: Drug: Ibrutinib
3 Recruiting Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia
Condition: Waldenström's Macroglobulinemia
Interventions: Drug: Ibrutinib;   Drug: Placebo;   Drug: Rituximab
4 Recruiting Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Conditions: Diffuse Large B Cell Lymphoma Relapsed;   Diffuse Large B Cell Lymphoma Refractory
Interventions: Drug: Ibrutinib, DA-EPOCH-R;   Drug: Ibrutinib, Lenalidomide, DA-EPOCH-R
5 Recruiting Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)
Condition: Metastatic Pancreatic Adenocarcinoma
Interventions: Drug: Ibrutinib;   Drug: Gemcitabine;   Drug: Nab-paclitaxel
6 Recruiting Ibrutinib in Combination With Lenalidomide, With and Without Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions: Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
7 Recruiting A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Conditions: Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma
Interventions: Drug: Ibrutinib;   Drug: MEDI4736
8 Recruiting A Multicenter Open-Label Phase 2a Study of Ibrutinib With or Without Cytarabine in Subjects With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia (AML)
Interventions: Drug: Ibrutinib;   Drug: LD-AraC
9 Recruiting A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL
Conditions: Chronic Lymphocytic Leukemia;   Small-Cell Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Obinutuzumab;   Drug: Chlorambucil
10 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo;   Drug: Dexamethasone
11 Not yet recruiting Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Interventions: Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Pneumococcal 13-valent Conjugate Vaccine;   Other: Quality-of-Life Assessment;   Biological: Trivalent Influenza Vaccine
12 Recruiting A Study of Ibrutinib Plus Rituximab With Hyper-CVAD Consolidation in Newly Diagnosed Young Patients With Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: G-CSF;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Citrovorum
13 Recruiting A Phase I/II Study of Ibrutinib in Previously Treated Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer
Condition: Lung Cancer
Intervention: Drug: Ibrutinib
14 Not yet recruiting Ibrutinib in Combination With GA101 (Obinutuzumab) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Patients.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: GA101;   Drug: ibrutinib
15 Recruiting Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Conditions: T-cell Lymphoma;   Relapsed and Refractory T-cell Lymphoma
Intervention: Drug: Ibrutinib
16 Not yet recruiting Ibrutinib Post Stem Cell Transplantation (SCT) in Double-Hit B-Cell Lymphoma
Condition: Lymphoma
Intervention: Drug: Ibrutinib
17 Recruiting A Phase I/II Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
18 Recruiting A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia
Conditions: Chronic Lymphocytic Leukemia;   Leukemia
Interventions: Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
19 Recruiting Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL)
Condition: Leukemia
Interventions: Drug: Ibrutinib;   Drug: Rituximab
20 Recruiting A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma
Condition: Lymphoma
Interventions: Drug: Bendamustine;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: PCI-32765 (Ibrutinib);   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results    Last Page
Indicates status has not been verified in more than two years